Silo Pharma, Inc. entered into Agreement with Many Ads Inc. (effective 2025-07-29).
“On July 29, 2025, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Many Ads Inc. (the “Seller”).”
Silo Pharma, Inc. — fact timeline
Source-grounded facts extracted from Silo Pharma, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Silo Pharma, Inc. issued 848,320 shares of Common Stock of common stock to investor relations consultant for commitment fee of $250,000.
“On February 20, 2026, Silo Pharma, Inc. (the “Company”) entered into an addendum to Service Agreement with its investor relations consultant pursuant to which is agreed to pay such consultant a commitment fee of $250,000 (the “Commitment Fee”) in consideration of entering into the addendum and restarting the service agreement. The consultant elected to receive the Commitment Fee in shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”) resulting in 848,320 shares of Common Stock payable to the consultant in respect of the Commitment Fee based on a $0.2947 share price”
Silo Pharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“June 27, 2025, the Company received a notification (the “Notification Letter”) from The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The Company init”
Silo Pharma, Inc. issued shares of common stock underlying such unregistered warrants of common stock to unknown for upon exercise of warrants.
“The unregistered warrants described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying such unregistered warrants, have not been registered under the Securities Act, or applicable state securities laws.”
Silo Pharma, Inc. issued warrants to purchase up to 2,857,143 shares of common stock of warrant to unknown for exercise price of $0.75 per share.
“In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 2,857,143 shares of common stock at an exercise price of $0.75 per share that will be immediately exercisable upon issuance and will expire five years from the effective date of a registration statement registering for resale the shares of common stock underlying the warrants.”
Silo Pharma, Inc. issued 2,857,143 shares of common stock of common stock to unknown for purchase price of $0.875 per share.
“and psychedelic treatments, today announced that it has entered into definitive agreements for the purchase and sale of 2,857,143 shares of common stock at a purchase price of $0.875 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up”
Silo Pharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“June 27, 2025, Silo Pharma, Inc. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based o”
Silo Pharma, Inc. shareholders approved Reincorporation from the State of Delaware to the State of Nevada at the 2023-12-11 meeting.
“The result of the votes to approve the Reincorporation was as follows: . For Against Abstain Broker Non-Vote 1,589,197 43,858 10,276 40,875”
Silo Pharma, Inc.: Decreased authorized shares of common stock from 500,000,000 to 100,000,000 (effective 2023-12-04).
“On December 4, 2023, the Company filed a Certificate of Amendment (the “Amendment”) to its Certificate of Incorporation with the Delaware Secretary of State to decrease its authorized shares of common stock from 500,000,000 shares to 100,000,000 shares.”
Silo Pharma, Inc. shareholders approved Ratification of appointment of Salberg & Company, P.A. as independent public accountant at the 2023-12-04 meeting.
“The result of the votes to approve Salberg & Company, P.A. was as follows: For Against Abstain 1,510,892 189 66,435”
Silo Pharma, Inc. shareholders approved Amendment to Certificate of Incorporation to decrease authorized shares from 500,000,000 to 100,000,000 at the 2023-12-04 meeting.
“The result of the votes to approve the Share Decrease Proposal was as follows: For Against Abstain Broker Non-Vote 1,523,993 2,648 10,000 40,875”
Silo Pharma, Inc. shareholders approved Approval of Amended and Restated 2020 Omnibus Equity Incentive Plan at the 2023-12-04 meeting.
“The result of the votes to approve the Amended 2020 Plan was as follows: For Against Abstain Broker Non-Vote 1,427,100 97,553 11,988 40,875”
Silo Pharma, Inc. shareholders approved Election of four directors at the 2023-12-04 meeting.
“The result of the votes to elect the four directors was as follows: Directors For Withheld Broker Non-Votes Eric Weisblum 1,448,375 88,266 40,875 Wayne D. Linsley 1,406,716 129,925 40,875 Dr. Kevin Muñoz 1,422,577 114,064 40,875 Dr. Jeff Pavell 1,448,425 88,216 40,875”
Silo Pharma, Inc. amended Third Amendment to Master License Agreement with University of Maryland, Baltimore valued at amended and restated schedule of diligence milestones (effective 2023-11-10).
“On November 10, 2023, our wholly-owned subsidiary Silo Pharma, Inc., a Florida corporation entered into a Third Amendment to Master License Agreement (the “Third Amendment”) with the University of Maryland, Baltimore, pursuant to which the parties agreed to an amended and restated schedule of diligence milestones for the Master License Agreement.”
Eric Weisblum was appointed as Chief Executive Officer at Silo Pharma, Inc..
“On October 12, 2022, the Company entered into an employment agreement with Eric Weisblum (the “Weisblum Employment Agreement”)”
Jeff Pavell was appointed as Director at Silo Pharma, Inc..
“On September 27, 2022, the Company’s Board of Directors (the “Board”) appointed Jeff Pavell as a member of the Board.”
Daniel Ryweck was appointed as Chief Financial Officer at Silo Pharma, Inc..
“On September 27, 2022, the Board appointed Daniel Ryweck as Chief Financial Officer of the Company”
Eric Weisblum resigned as Chief Financial Officer at Silo Pharma, Inc..
“On September 27, 2022, Eric Weisblum resigned as our Chief Financial Officer.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.